AstraZeneca Plc’s Greatest Strengths

Two standout factors supporting an investment in AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When I think of pharmaceutical company AstraZeneca (LSE: AZN) (NYSE: AZN.US), two factors jump out at me as the firm’s greatest strengths and top the list of what makes the company  attractive as an investment proposition.

1) Promising product development pipeline

AstraZeneca’s turnover and profits have dwindled in recent years thanks to increased competition after some the firm’s bestselling drugs emerged from periods of patent protection. However, the firm is building up an exciting pipeline of new products, each a potential blockbuster, and forward-looking investors are driving the share price higher in anticipation of better times ahead.

astrazenecaThe path from test tube to medicine cabinet is long, torturous, time-consuming and expensive. Something like one or two compounds in 10,000 tested end up as licensed treatments. Scientists carry out testing along the way in phases in order to comply with regulation, but phase three is the step before licensing, so when a formulation is approaching phase three testing, investors tend to get excited. However, there’s many a slip between cup and lip, leading to some potential treatments getting the chop even at that stage after, perhaps, many years of development activity.

Right now, AstraZeneca reckons it has 11 new molecular entities in Phase III or registration; almost double compared with last year. There are also 19 candidates for potential new Phase III starts in 2014-15. Such late-stage development activity is a key factor in achieving a return to revenue and earnings’ growth.

2) Firm cash flow

Although revenue and profits are struggling, cash flow is holding up quite well:

Year to December 2009 2010 2011 2012 2013
Revenue ($m) 32,804 33,269 33,591 27,973 25,711
Net cash from   operations ($m) 11,739 10,680 7,821 6,948 7,400
Adjusted earnings   per share (cents) 632 671 728 641 505

A strong cash flow performance seems to provide support for the share price. As long as AstraZeneca generates cash, it can keep recycling funds into R&D and pay dividends to investors. Cash flow is an important figure to watch while we wait for new products to boost revenue and profits.

What now?

Right now AstraZeneca seems to attract mainly as a turnaround proposition. It’s conceivable that a return to growth could occur as new products take off.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin does not own shares in AstraZeneca.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »